Biosense Webster has announced that the US FDA has received FDA approval to market the NAVISTAR RMT THERMOCOOL Catheter. The catheter is intended to maintain safe tip-to-tissue temperatures and gives physicians the safety and convenience of steering the catheter remotely and away from fluoroscopy exposure during procedures. This helps to eliminate abnormal heart rhythms namely atrial flutter and recurrent drug/device refractory sustained monomorphic ventricular tachycardia (VT) due to prior myocardial infarction (MI) in adults. The NAVISTAR RMT THERMOCOOL Catheter for radiofrequency (RF) ablation is used with the NIOBE Magnetic Navigation System, which helps steer a catheter remotely and guide ablation to targeted areas that require treatment. NAVISTAR RMT THERMOCOOL Catheter used in combination with the CARTO RMT System creates highly accurate three dimensional (3D) electroanatomical maps. Electrophysiologists are able to steer the NAVISTAR RMT THERMOCOOL Catheter using the integrated NIOBE Navigation technology and a miniature location sensor is placed inside each catheter for real-time, high-resolution mapping. RF Ablation procedure consists in guiding the NAVISTAR RMT THERMOCOOL Catheter with the NIOBE Magnetic Navigation System to the area of heart muscle where cells are giving off electrical signals that stimulate the abnormal heart rhythm. An application of energy is then transmitted to those areas to carefully destroy those heart muscle cells that are conducting the extra impulses that caused the irregular heart rhythm.